Diseases & Longevity · File 28

Rheumatoid arthritis. Systemic autoimmune — real mortality is cardiovascular, not articular.

Rheumatoid arthritis affects approximately 0.5-1% of adults globally. It was taught as a "joint disease" — but the reality is that real mortality in RA is predominantly cardiovascular, not articular. Chronic systemic inflammation accelerates atherosclerosis (Avina-Zubieta 2008). Longevity medicine in RA does not compete with rheumatology — it addresses the added cardiovascular risk and systemic comorbidities that articular management does not.

Why RA is cardiovascular disease in addition to articular

Rheumatoid arthritis chronic synovitis is the visible tip of sustained systemic inflammation. That inflammation — pro-inflammatory cytokines (TNF-α, IL-6, IL-17), elevated hsCRP and fibrinogen, endothelial dysfunction — produces a phenotype of accelerated atherosclerosis. The patient with poorly controlled RA has cardiovascular risk comparable to a diabetic patient without RA — and that is independent of traditional risk factors.

EULAR 2023 formalized this recognition: guidelines recommend systematic CV risk screening (multiplied by 1.5 in RA), intensive control of traditional factors, and above all, inflammatory treat-to-target — because systemic inflammation control reduces added CV risk. Biologics (anti-TNF, anti-IL6) and JAK-i have transformed prognosis when titrated to target. Longevity medicine operates on added CV risk and comorbidities — coordinating with rheumatology.

RA is not just articular — it's silent cardiovascular disease. Ignoring the added CV risk is ignoring the true mortality determinant.
CV risk vs general population

The real weight, in numbers

Data come from cardiovascular meta-analyses in RA, EULAR, national registries, and biologic trials. They reflect the magnitude of added CV risk.

  • Prevalence

    ~0.5-1% adultos

    RA affects approximately 0.5-1% of adults globally, with 3:1 female predominance. Peak presentation is 40-60 — period of full work activity and early CV.
    — Smolen et al., Nat Rev Dis Primers 2018

  • Increased CV risk

    ×1.5 vs general

    Meta-analyses (Avina-Zubieta 2008) show RA patients have approximately 50% higher cardiovascular mortality risk vs general population — independent of traditional factors. EULAR multiplies SCORE by 1.5 in RA.
    — Avina-Zubieta et al., Arthritis Rheum 2008

  • Treat-to-target

    EULAR 2023

    EULAR 2023 confirms inflammatory treat-to-target as standard — sustained activity control (DAS28, CDAI) reduces joint damage and CV mortality. Conventional DMARDs first line + biologics / JAK-i if insufficient.
    — Smolen et al., Ann Rheum Dis 2023

  • Biologics transformed prognosis

    Anti-TNF, anti-IL6, JAK-i

    Anti-TNF (etanercept, adalimumab, infliximab), anti-IL6 (tocilizumab, sarilumab), JAK inhibitors (tofacitinib, baricitinib, upadacitinib) — significantly transformed moderate-severe RA prognosis. They reduce activity, damage, and CV mortality.
    — Smolen et al., Nat Rev Dis Primers 2018

Chap. 03 · Autoimmune-cardiovascular-functional

The systemic cluster that longevity medicine complements

The rheumatologist controls articular activity. The systemic cluster — added CV risk, sarcopenia, secondary osteoporosis, depression — is where longevity complements.

  • Rheumatoid sarcopenia

    Caquexia inflamatoria

    Poorly controlled RA produces "rheumatoid cachexia" — muscle mass loss with preserved fat — from chronic inflammaging. Mortality and disability predictor. Body composition (DEXA) and strength are longevity follow-up axes.
    — Summers et al., Rheumatol Int 2008

  • Secondary osteoporosis

    Inflamación + corticoide

    Chronic systemic inflammation + prolonged corticosteroid use significantly increases osteoporosis and fracture risk. DEXA screening + proactive management (vitamin D, calcium, bisphosphonates when indicated) is standard.
    — Gough et al., Arthritis Rheum 1994; ACR Guidelines

  • Quality of life and depression

    Dolor + estigma + fatiga

    RA significantly reduces SF-36 (PCS and MCS) — joint pain, fatigue, social stigma, functional deterioration. Clinical depression coexists in 15-30% of patients and worsens activity. Structured psychosocial approach is integral.
    — Margaretten et al., Arthritis Care Res 2011

  • Pulmonary cluster

    ILD asociada a AR

    RA can develop interstitial lung disease (RA-ILD) — mortality predictor. Screening with pulmonary function and high-resolution CT when clinical suspicion. Management decision with pulmonology and rheumatology jointly.
    — Bongartz et al., Arthritis Rheum 2010

What we don't offer — and what we do

Wellness Care does not prescribe DMARDs or biologics. Choice of methotrexate, leflunomide, anti-TNF, anti-IL6, JAK inhibitors, activity monitoring (DAS28), management of associated autoimmune comorbidities, and surgical decisions belong to the rheumatologist. What we do: cardiovascular and systemic longevity view — intensified CV risk (with advanced biomarkers), rheumatoid sarcopenia, secondary osteoporosis, mental health, cardiometabolic cluster optimization.

We evaluate patients with diagnosed RA under rheumatology management who: have unproactively-addressed added cardiovascular risk, present with sarcopenia / rheumatoid cachexia, secondary osteoporosis from prolonged corticosteroid, depression / anxiety comorbidity, or want to optimize systemic longevity trajectory. Coordination with rheumatology, cardiology, and endocrinology always when indicated.

RA requires rheumatology. But added CV risk and systemic cluster require longevity view. That coordination changes real trajectory.
How we measure it

How the systemic cluster
is addressed at Wellness Care

Intensified CV risk + rheumatoid sarcopenia + secondary osteoporosis + mental health + cardiometabolic cluster optimization. In rheumatology coordination always.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications — EULAR 2023, CV mortality in RA, rheumatoid sarcopenia, RA-ILD.

«Las recomendaciones EULAR 2023 confirman treat-to-target como estándar — control sostenido de actividad inflamatoria reduce daño articular y mortalidad cardiovascular.»
Ann Rheum Dis · 2023
Smolen et al., Ann Rheum Dis 2023
EULAR Treat-to-target
«Los pacientes con AR tienen aproximadamente un 50% más de riesgo de mortalidad cardiovascular vs población general — independiente de factores tradicionales.»
Arthritis Rheum · 2008
Avina-Zubieta et al., 2008
Meta-análisis mortalidad CV
«La caquexia reumatoide — pérdida muscular con grasa preservada — predice mortalidad y discapacidad en AR. Medirla y manejarla es esencial.»
Rheumatol Int · 2008
Summers et al., Rheumatol Int 2008
Caquexia reumatoide

Frequently asked questions about rheumatoid arthritis

The most recurrent questions about RA — added cardiovascular risk, treat-to-target, biologics, and why longevity medicine complements rheumatology.

01

Why does RA increase cardiovascular risk?

Due to chronic systemic inflammation.

Mechanisms:

· Pro-inflammatory cytokines — TNF-α, IL-6, IL-17
· Sustained elevation of hsCRP and fibrinogen
· Endothelial dysfunction
· Inflammatory dyslipidemia

Produce accelerated atherosclerosis.

CV risk in RA is comparable to a diabetic patient — EULAR multiplies SCORE by 1.5.

Sustained inflammatory activity control (treat-to-target) reduces that added risk.

02

What does treat-to-target mean in RA?

It's the modern management strategy:

1. Define clear target:

· Remission or low activity
· Measured with DAS28, CDAI, or SDAI

2. Adjust treatment systematically until reaching it

3. Maintain sustained control

EULAR 2023 confirmed it as standard.

Therapeutic escalation if target not reached:

· Conventional DMARDs → biologics → JAK-i

Final decision by rheumatology.

03

Does RA predispose me to osteoporosis?

Yes, dual pathway:

1. Chronic systemic inflammation:

· Increases bone resorption (elevated RANKL)

2. Prolonged corticosteroid use:

· Induces glucocorticoid-induced osteoporosis (GIO)

Modern standard:

· DEXA at diagnosis and periodic
· Vitamin D, calcium
· Strength exercise
· Bisphosphonates / denosumab when indicated

ACR has specific GIO guidelines.

04

Is exercise safe with RA?

Yes — and necessary.

EULAR and ACR recommend aerobic exercise + progressive strength training in RA patients.

Benefits:

· Reduces pain
· Improves function
· Counteracts rheumatoid cachexia
· Improves CV risk factors
· Improves quality of life

Adapt to joint activity:

· In flares → isometric and range of motion
· In remission → strength and cardio

Coordination with physiatry / physiotherapy.

05

When should I consult?

An integrated assessment is worthwhile if:

· Diagnosed RA under rheumatology management but added CV risk not proactively addressed
· Sarcopenia / rheumatoid cachexia
· Secondary osteoporosis
· Amplified cardiometabolic cluster
· Comorbid depression / anxiety
· Suspected RA-ILD or other systemic comorbidities
· Want to understand shared biological axes — inflammaging, advanced lipid profile

The assessment complements rheumatology — does not replace it.

Beyond the joint

RA is not just articular — it's silent cardiovascular disease with systemic inflammaging. That reading changes longevity management.

Intensified CV risk, rheumatoid sarcopenia, secondary osteoporosis, mental health, and cardiometabolic cluster — all in rheumatology coordination. That integration changes trajectory.

Diagnosed RA with unaddressed comorbidities?

Book a comprehensive longevity assessment with RA

We evaluate intensified cardiovascular risk (ApoB, Lp(a), hsCRP, endothelial function), sarcopenia, secondary osteoporosis, body composition, mental health, and 14 Lancet Commission factors. The assessment complements rheumatology — does not replace it in DMARD or biologic decisions.

Book comprehensive assessment with RA